Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

SEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that six abstracts highlighting preclinical data from the fusogen platform have been accepted for presentation, including two oral presentations, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting taking place May 16-20, 2023 in Los Angeles, CA.

Oral Presentations:

Title: A Novel Technique to Detect Peripheral Blood CAR+ T Cells Using RNAscope In Situ Hybridization (ISH) in Non-Human Primates and Mice
Summary: A novel cell-block method can be used to detect circulating CAR T cells in preclinical studies by evaluating the expression of Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE) by Fluorescence in situ hybridization (FISH) in lieu of flow cytometry or PCR.
Session: Pharmacology/Toxicology Studies: Bio Distribution
Session Location: Petree Hall C
Session Date/Time: Friday, May 19, 2023; 3:45 p.m. – 5:30 p.m. PT
Presentation Time: 5:00 p.m. – 5:15 p.m. PT
Abstract Number: 240
Title: Target Cell and Tissue Specificity of a Novel CD8-Targeted Fusosome for Direct In Vivo Delivery of CD19 or a CD20 CAR to CD8+ T Cells
Summary: A panel of in vitro studies confirmed cell-specific transduction, CAR Expression, and target cell killing, supporting safe in vivo administration of Sana’s novel CD8-directed fusosomes for CAR T therapies.
Session: Pharmacology/Toxicology Studies: In Vitro and In Vivo Safety
Session Location: Petree Hall C
Session Date/Time: Saturday, May 20, 2023; 8:00 a.m. – 9:45 a.m. PT
Presentation Time: 9:15 a.m. – 9:30 a.m. PT
Abstract Number: 317

Poster Presentations:

Title: Advancements in Manufacturing of CD8-Targeted Fusosomes Enhance Transduction of Resting T Cells In Vitro and In Vivo
Summary:  Process improvements were made to the manufacturing of Sana’s CD8 targeted fusosome for in vivo CAR T therapy, resulting in enhanced resting T cell transduction and in vitro and in vivo tumor killing.
Session:  Wednesday Poster Session
Session Date/Time: Wednesday, May 17, 2023; 12:00 p.m. PT
Abstract Number: 760
Title: Temsirolimus and IL-7 Treatment Synergistically Increase Primary Resting CD8+ T Cell Transduction with CD8-Targeted Fusosomes and Enhance CD19CAR Expression
Summary: The use of IL-7 and Rapamycin analogs (Rapalogs) with Sana’s CD8 targeted fusosomes is able to increase fusosome potency and improves the ability to deliver a therapeutic CAR transgene.
Session: Thursday Poster Session
Session Date/Time: Thursday, May 18, 2022; 12:00 p.m. PT
Abstract Number: 1058
Title:  In Vivo Delivery of Genetic Payloads to Human Hematopoietic Stem/Progenitor Cells
Summary: A robust strategy for establishing basal access and achieving efficient and specific in vivo delivery of genetic payloads to human hematopoietic stem and progenitor cells (HSPC) was established.
Session: Thursday Poster Session
Session Date/Time: Thursday, May 18, 2023; 12:00 p.m. PT
Abstract Number: 1017
Title: The Retargeted Universal Fusosome: A Modular Approach to Generate Fusosomes for Targeted Gene Delivery
Summary: A modular approach to developing retargetable fusosomes decouples production and targeting, offering an efficient method to identify potent candidates for cell-specific gene delivery.
Session: Thursday Poster Session
Session Date/Time: Thursday, May 18, 2023; 12:00 p.m. PT
Abstract Number: 970

The ASGCT abstracts are available to the public at:

About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more information about Sana Biotechnology, please visit

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision; expectations for the Company’s participation at the American Society of Gene and Cell Therapy 26th Annual Meeting; and expectations for the Company’s presentations at such meeting, including the content of such presentations. and expectations for its development programs, product candidates and technology platforms, including with respect to clinical trials and expected timing and impact thereof; and expectations for hosting a potential R&D Day event, including the timing of and subject matter of the presentations at such event. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market, and other disruptions, including due to the COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K dated March 16, 2023. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media:
Nicole Keith

Primary Logo

Back to news